Andrew J Pugely1, Nicholas A Bedard2, Piyush Kalakoti2, Nathan R Hendrickson2, Jamal N Shillingford3, Joseph L Laratta3, Comron Saifi4, Ronald A Lehman3, K Daniel Riew3. 1. Orthopaedic Surgery, University of Iowa Hospitals & Clinics, Iowa City, IA 52242, USA; Orthopaedic Surgery, Columbia University Medical Center, The Spine Hospital, New York-Presbyterian Healthcare System, New York, NY 10034, USA. Electronic address: andrew-pugely@uiowa.edu. 2. Orthopaedic Surgery, University of Iowa Hospitals & Clinics, Iowa City, IA 52242, USA. 3. Orthopaedic Surgery, Columbia University Medical Center, The Spine Hospital, New York-Presbyterian Healthcare System, New York, NY 10034, USA. 4. Orthopaedic Surgery, Perelman School of Medicine, University of Pennsylvania, PA 19107, USA.
Abstract
BACKGROUND CONTEXT: Limited or no data exist evaluating risk factors associated with prolonged opioid use following cervical arthrodesis. PURPOSE: The objectives of this study were to assess trends in postoperative narcotic use among preoperative opioid users (OUs) versus non-opioid users (NOUs) and to identify factors associated with postoperative narcotic use at 1 year following cervical arthrodesis. STUDY DESIGN/ SETTING: This is a retrospective observational study. PATIENT SAMPLE: The patient sample included 17,391 patients (OU: 52.4%) registered in the Humana Inc claims dataset who underwent anterior cervical fusion (ACF) or posterior cervical fusion (PCF) between 2007 and 2015. OUTCOME MEASURES: Prolonged opioid usage was defined as narcotic prescription filling at 1 year following cervical arthrodesis. METHODS: Based on preoperative opioid use, patients were identified as an OU (history of narcotic prescription filled within 3 months before surgery) or a NOU (no preoperative prescription). Rates of opioid use were evaluated preoperatively for OU and trended for 1 year postoperatively for both OU and NOU. Multivariable regression techniques investigated factors associated with the use of narcotics at 1 year following ACF and PCF. Based on the model findings, a web-based interactive app was developed to estimate 1-year postoperative risk of using narcotics following cervical arthrodesis (http://neuro-risk.com/opiod-use/ or https://www.neurosurgerycost.com/opioid/opioid_use). RESULTS: Overall, 87.4% of the patients (n=15,204) underwent ACF, whereas 12.6% (n=2187) underwent PCF. At 1 month following surgery, 47.7% of NOUs and 82% of OUs had a filled opioid prescription. Rates of prescription opioids declined significantly to 7.8% in NOUs versus 50.5% in OUs at 3 months, but plateaued at the 6- to 12-month postoperative period (NOU: 5.7%-6.7%, OU: 44.9%-46.9%). At 1 year, significantly higher narcotic prescription filling rates were observed in OUs compared with NOUs (45.3% vs. 6.3%, p<.001). Preoperative opioid use was a significant driver of 1-year narcotic use following ACF (odds ratio [OR]: 7.02, p<.001) and PCF (OR: 6.98, p<.001), along with younger age (≤50 years), history of drug dependence, and lower back pain. CONCLUSIONS: Over 50% of the patients used opioids before cervical arthrodesis. Postoperative opioid use fell dramatically during the first 3 months in NOU, but nearly half of the preoperative OUs will remain on narcotics at 1 year postoperatively. Our findings serve as a baseline in identifying patients at risk of chronic use and encourage discontinuation of opioids before cervical spine surgery.
BACKGROUND CONTEXT: Limited or no data exist evaluating risk factors associated with prolonged opioid use following cervical arthrodesis. PURPOSE: The objectives of this study were to assess trends in postoperative narcotic use among preoperative opioid users (OUs) versus non-opioid users (NOUs) and to identify factors associated with postoperative narcotic use at 1 year following cervical arthrodesis. STUDY DESIGN/ SETTING: This is a retrospective observational study. PATIENT SAMPLE: The patient sample included 17,391 patients (OU: 52.4%) registered in the Humana Inc claims dataset who underwent anterior cervical fusion (ACF) or posterior cervical fusion (PCF) between 2007 and 2015. OUTCOME MEASURES: Prolonged opioid usage was defined as narcotic prescription filling at 1 year following cervical arthrodesis. METHODS: Based on preoperative opioid use, patients were identified as an OU (history of narcotic prescription filled within 3 months before surgery) or a NOU (no preoperative prescription). Rates of opioid use were evaluated preoperatively for OU and trended for 1 year postoperatively for both OU and NOU. Multivariable regression techniques investigated factors associated with the use of narcotics at 1 year following ACF and PCF. Based on the model findings, a web-based interactive app was developed to estimate 1-year postoperative risk of using narcotics following cervical arthrodesis (http://neuro-risk.com/opiod-use/ or https://www.neurosurgerycost.com/opioid/opioid_use). RESULTS: Overall, 87.4% of the patients (n=15,204) underwent ACF, whereas 12.6% (n=2187) underwent PCF. At 1 month following surgery, 47.7% of NOUs and 82% of OUs had a filled opioid prescription. Rates of prescription opioids declined significantly to 7.8% in NOUs versus 50.5% in OUs at 3 months, but plateaued at the 6- to 12-month postoperative period (NOU: 5.7%-6.7%, OU: 44.9%-46.9%). At 1 year, significantly higher narcotic prescription filling rates were observed in OUs compared with NOUs (45.3% vs. 6.3%, p<.001). Preoperative opioid use was a significant driver of 1-year narcotic use following ACF (odds ratio [OR]: 7.02, p<.001) and PCF (OR: 6.98, p<.001), along with younger age (≤50 years), history of drug dependence, and lower back pain. CONCLUSIONS: Over 50% of the patients used opioids before cervical arthrodesis. Postoperative opioid use fell dramatically during the first 3 months in NOU, but nearly half of the preoperative OUs will remain on narcotics at 1 year postoperatively. Our findings serve as a baseline in identifying patients at risk of chronic use and encourage discontinuation of opioids before cervical spine surgery.
Authors: Ruchir N Karmali; Christopher Bush; Sudha R Raman; Cynthia I Campbell; Asheley C Skinner; Andrew W Roberts Journal: Pharmacoepidemiol Drug Saf Date: 2019-12-18 Impact factor: 2.890
Authors: Hannah Wunsch; Andrea D Hill; Longdi Fu; Rob A Fowler; Han Ting Wang; Tara Gomes; Eddy Fan; David N Juurlink; Ruxandra Pinto; Duminda N Wijeysundera; Damon C Scales Journal: Am J Respir Crit Care Med Date: 2020-08-15 Impact factor: 21.405
Authors: Alexandra Stratton; Eugene Wai; Stephen Kingwell; Philippe Phan; Darren Roffey; Mohamed El Koussy; Sean Christie; Peter Jarzem; Parham Rasoulinejad; Steve Casha; Jerome Paquet; Michael Johnson; Edward Abraham; Hamilton Hall; Greg McIntosh; Kenneth Thomas; Raja Rampersaud; Neil Manson; Charles Fisher Journal: Can J Surg Date: 2020-05-28 Impact factor: 2.089
Authors: Harjot Singh Uppal; Sydney Ilana Rozenfeld; Scott Hetzel; Kristin Nicole Hesselbach; Trisha Ludwig; Miranda Bice; Seth K Williams Journal: N Am Spine Soc J Date: 2022-06-20
Authors: Paul Inclan; Travis S CreveCoeur; Shay Bess; Jeffrey L Gum; Breton G Line; Lawrence G Lenke; Michael P Kelly Journal: Spine Deform Date: 2022-01-27
Authors: Naheed K Jivraj; Faizal Raghavji; Jennifer Bethell; Duminda N Wijeysundera; Karim S Ladha; Brian T Bateman; Mark D Neuman; Hannah Wunsch Journal: Anesthesiology Date: 2020-06 Impact factor: 7.892
Authors: Hannah A Levy; Brian A Karamian; Jeffrey Henstenburg; Joseph Larwa; Jose A Canseco; Brett Haislup; Michael Chang; Parthik Patel; Kris E Radcliff; Barrett I Woods; Mark F Kurd; Alan S Hilibrand; Christopher K Kepler; Alexander R Vaccaro; Gregory D Schroeder Journal: J Orthop Date: 2021-06-30
Authors: Rafa Rahman; Sara Wallam; Bo Zhang; Rahul Sachdev; Emmanuel L McNeely; Khaled M Kebaish; Lee H Riley; David B Cohen; Amit Jain; Sang H Lee; Daniel M Sciubba; Richard L Skolasky; Brian J Neuman Journal: World Neurosurg Date: 2021-03-19 Impact factor: 2.210